FREE DELIVERY ON ALL ORDERS OVER £29*

*Conditions apply - details
Shop by Category
Please enable cookies to use this site. Why?

Veraflox

Veraflox® is the first next-generation veterinary fluoroquinolone antibiotic for the treatment of bacterial infection in cats and dogs. Veraflox Flavoured Tablets are available for both cats and dogs in 3 strengths: 15mg, 60mg and 120mg. Veraflox Oral Suspension 15ml is also available for cats.

Veraflox Flavoured Tablets 15mg

Veraflox Flavoured Tablets 15mg

£0.73

Veraflox Flavoured Tablets 15mg is indicated for the treatment of bacterial infection in both cats and dogs. Tablets sold individually. Legal Category: Pom-V | Veraflox Tablets[More info]

£0.73
Veraflox Flavoured Tablets 60mg

Veraflox Flavoured Tablets 60mg

£1.75

Veraflox Flavoured Tablets 60mg is indicated for the treatment of bacterial infection in both cats and dogs. Tablets sold individually. Legal Category: Pom-V | Veraflox Tablets[More info]

£1.75
Veraflox Flavoured Tablets 120mg

Veraflox Flavoured Tablets 120mg

£2.62

Veraflox Flavoured Tablets 120mg is indicated for the treatment of bacterial infection in both cats and dogs. Tablets sold individually. Legal Category: Pom-V | Veraflox Tablets[More info]

£2.62
Veraflox Oral Suspension 15ml

Veraflox Oral Suspension 15ml

£9.70

Veraflox Oral Suspension 15ml is indicated for treatment of bacterial infection in cats. The specially developed, highly palatable formula and mess-free syringe makes it easier to be...[More info]

£9.70

Uses

Cats: Treatment of acute infections of the upper respiratory tract caused by susceptible strains of Pasteurella multocida, Escherichia coli and the Staphylococcus intermedius group (including S. pseudintermedius).

Dogs: Treatment of:

  • wound infections caused by susceptible strains of the Staphylococcus intermedius group (including S.pseudintermedius)
  • superficial and deep pyoderma caused by susceptible strains of the Staphylococcus intermedius group (including S. pseudintermedius)
  • acute urinary tract infections caused by susceptible strains of Escherichia coli and the Staphylococcus intermedius group (including S. pseudintermedius) and
  • as adjunctive treatment to mechanical or surgical periodontal therapy in the treatment of severe infections of the gingiva and periodontal tissues caused by susceptible strains of anaerobic organisms, for example Porphyromonas spp. and Prevotella spp.

Contra-indications, warnings, etc
Do not use in animals with known hypersensitivity to fluoroquinolones.

Cats: Due to the lack of data, pradofloxacin should not be used in kittens aged less than 6 weeks. Pradofloxacin has no effects on the developing cartilage of kittens of 6 weeks of age and older. However, the product should not be used in cats with persisting articular cartilage lesions, as these lesions may worsen during treatment with fluoroquinolones.
Do not use in cats with central nervous system (CNS) disorders, such as epilepsy, as fluoroquinolones could potentially cause seizures in predisposed animals.
Do not use in cats during pregnancy and lactation.

Dogs: Do not use in dogs during the period of growth as developing articular cartilage may be affected. The period of growth depends on the breed. For the majority of breeds, pradofloxacin-containing veterinary medicinal products must not be used in dogs of less than 12 months of age and in giant breeds less than 18 months.
Do not use in dogs with persisting articular cartilage lesions, since lesions may worsen during treatment with fluoroquinolones.
Do not use in dogs with central nervous system (CNS) disorders, such as epilepsy, as fluoroquinolones could possibly cause seizures in predisposed animals.
Do not use in dogs during pregnancy and lactation.
Whenever possible, the veterinary medicinal product should only be used based on susceptibility testing. Official and local antimicrobial policies should be taken into account when the veterinary medicinal product is used.
Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials.
Use of the veterinary medicinal product deviating from instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other fluoroquinolones due to the potential for cross-resistance.
Pyoderma occurs mostly secondary to an underlying disease, thus, it is advisable to determine the underlying cause and to treat the animal accordingly.
This veterinary medicinal product should only be used in severe cases of periodontal disease. Mechanical cleaning of teeth and removal of plaque and calculus or extraction of teeth are prerequisites for a persistent therapeutic effect. In case of gingivitis and periodontitis, the veterinary medicinal product should only be used as an adjunct to mechanical or surgical periodontal therapy. Only those dogs for which periodontal treatment goals cannot be achieved by mechanical treatment alone should be treated with this veterinary medicinal product.
Pradofloxacin may increase sensitivity of the skin to sunlight. During treatment, animals should therefore not be exposed to excessive sunlight.
Excretion via kidneys is an important elimination route for pradofloxacin in dogs. As for other fluoroquinolones, the renal excretion rate of pradofloxacin may be decreased in dogs with impaired kidney function and, therefore, pradofloxacin should be used with caution in such animals.
Mild transient gastro-intestinal disturbances including vomiting have been observed in rare cases in dogs and cats.
Concurrent administration with metal cations such as those contained in antacids or sucralfate made with magnesium hydroxide or aluminium hydroxide, or multivitamins containing iron or zinc, and dairy products containing calcium, has been reported to decrease the bioavailability of fluoroquinolones. Therefore, Veraflox should not be administered concurrently with antacids, sucralfate, multivitamins or dairy products, as absorption of Veraflox may be decreased.
Further, fluoroquinolones should not be used in combination with non-steroidal anti-inflammatory drugs (NSAIDs) in animals with a history of seizures because of potential pharmacodynamic interactions in the CNS.
The combination of fluoroquinolones with theophylline could increase the plasma levels of theophylline by altering its metabolism and thus should be avoided.
The combined use of fluoroquinolones with digoxin should also be avoided because of potentially increased oral bioavailability of digoxin.
No specific antidotes for pradofloxacin (or other fluoroquinolones) are known, therefore, in case of overdose, symptomatic treatment should be given.
Intermittent vomiting and soft faeces were observed in dogs after repeated oral administration of 2.7 times the maximum recommended dose. Infrequent vomiting was observed in cats after repeated oral administration of 2.7 times the maximum recommended dose.

User Safety
Due to potential harmful effects, the tablets must be kept out of the reach and sight of children.
People with known hypersensitivity to quinolones should avoid any contact with the veterinary medicinal product.
Avoid skin and eye contact with the veterinary medicinal product.
Wash hands after use.
Do not eat, drink or smoke while handling the veterinary medicinal product.
In case of accidental ingestion, seek medical advice and show the package leaflet or the label to the physician.

Environmental Safety
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Further information
Pharmacotherapeutic group: Antibacterials for systemic use, fluoroquinolones. ATCvet code: QJ01MA. The primary mode of action of the fluoroquinolones involves interaction with enzymes essential for major DNA functions such as replication, transcription and recombination. The primary targets for pradofloxacin are the bacterial DNA gyrase and topoisomerase IV enzymes. Reversible association between pradofloxacin and DNA gyrase or DNA topoisomerase IV in the target bacteria results in inhibition of these enzymes and rapid death of the bacterial cell. The rapidity and extent of bacterial killing are directly proportional to the drug concentration.
Although pradofloxacin has in-vitro activity against a wide range of Gram-positive and Gram-negative organisms, including anaerobic bacteria, this veterinary medicinal product should only be used for the approved indications and in accordance with the prudent use recommendations.

MIC-Data

Dogs:

Bacterial species
No. of strains
MIC50 (µg/ml)
MIC90 (µg/ml)
MIC range (µg/ml)
Staphylococcus intermedius group (incl S. pseudintermedius)
1097
0.062
0.062
0.002-4
Escherichia coli
173
0.031
0.062
0.008-16
Porphyromonas spp.
310
0.062
0.125
≤0.016-0.5
Prevotella spp.
320
0.062
0.25
≤0.016-1

The bacteria were isolated between 2001 and 2007 from clinical cases in Belgium, France, Germany, Hungary, Italy, Poland, Sweden and UK.

 

Cats:

Bacterial species
No. of Strains
MIC50(µg/ml)
MIC90(µg/ml)
MIC range (µg/ml)
Pasteurella multocida
323
0.016
0.016
0.002-0.062
Escherichia coli
135
0.016
4
0.008-8
Staphylococcus intermedius group (incl S. pseudintermedius)
184
0.062
0.125
0.016-8

The bacteria were isolated between 2001 and 2007 from clinical cases in Belgium, France, Germany, Hungary, Poland, Sweden and UK.

Resistance to fluoroquinolones has been reported to arise from five sources, (i) point mutations in the genes encoding for DNA gyrase and/or topoisomerase IV leading to alterations of the respective enzyme, (ii) alterations of drug permeability in Gram-negative bacteria, (iii) efflux mechanisms, (iv) plasmid mediated resistance and (v) gyrase protecting proteins. All mechanisms lead to a reduced susceptibility of the bacteria to fluoroquinolones. Cross-resistance within the fluoroquinolone class of antimicrobials is common.
In laboratory studies the bioavailability of pradofloxacin was reduced in fed dogs and cats compared to fasted animals. However in the clinical studies feeding did not reveal any impact on the treatment effect.

Dogs:
After oral administration of the therapeutic dose to dogs, pradofloxacin is rapidly (Tmax of 2 hours) and almost completely (approximately 100%) absorbed reaching peak concentrations of 1.6 mg/l.
A linear relationship between pradofloxacin serum concentrations and the administered dose is observed in dogs within a tested dose range of 1 to 9 mg/kg body weight. Long-term daily treatment has no impact on the pharmacokinetic profile, with an accumulation index of 1.1. In vitro plasma protein binding is low (35%). The high volume of distribution (Vd) >2 l/kg bodyweight indicates good tissue penetration. Pradofloxacin concentrations in skin homogenates of dogs exceed those in serum by up to seven times. Pradofloxacin is eliminated from serum with a terminal half-life of 7 hours. Major elimination pathways are glucuronidation as well as renal excretion. Pradofloxacin is cleared from the body at 0.24 l/h/kg. Approximately 40% of the administered product is excreted unchanged via the kidneys.

Cats:
In cats, absorption of orally administered pradofloxacin at the therapeutic dose is rapid reaching peak concentrations of 1.2 mg/l within 0.5 hours. The bioavailability of the tablet is at least 70%. Repeated dosing shows no impact on the pharmacokinetic profile (accumulation index = 1.0). In vitro plasma protein binding is low (30%). The high volume of distribution (Vd) >4 l/kg body weight indicates good tissue penetration. Pradofloxacin is eliminated from serum with a terminal half-life of 9 hours. The major elimination pathway in cats is glucuronidation. Pradofloxacin is cleared from the body at 0.28 l/h/kg.